Treatment effect, adherence, and safety of high fluid intake for the prevention of incident and recurrent kidney stones: a systematic review and meta-analysis
- 540 Downloads
The objective of this systematic review and meta-analysis were to evaluate the effectiveness of high fluid intake for the prevention of incident and recurrent kidney stones, as well as its adherence and safety.
A literature search was performed encompassing 1980 through July 2014. Studies that reported relative risks, odds ratios, or hazard ratios comparing the risk of kidney stone events in patients with high vs inadequate fluid intake were included. Pooled risk ratios (RRs) and 95 % confidence intervals (CIs) were calculated using a random-effect, generic inverse variance method.
Nine studies [2 randomized controlled trials (RCTs) with 269 patients; 7 observational studies with 273,685 individuals] were included in the meta-analysis. Pooled RRs of kidney stones in individuals with high-fluid intake were 0.40 (95 % CI 0.20–0.79) and 0.49 (0.34–0.71) in RCTs and observational studies, respectively. High fluid intake was significantly associated with reduced risk of recurrent kidney stones: RRs 0.40 (95 % CI 0.20–0.79) and 0.20 (0.09–0.44) in RCTs and observational studies, respectively. Adherence and safety data on high fluid intake treatment were limited; 1 RCT reported no withdrawals due to adverse events.
This analysis demonstrated a significantly reduced risk of incident kidney stones among individuals with high fluid consumption. High fluid consumption also reduced the risk of recurrent kidney stones. Furthermore, the magnitude of risk reduction was high. Although increased water intake appears to be safe, future studies on its safety in patients with high risk of volume overload or hyponatremia may be indicated.
KeywordsMeta-analysis Fluid intake Kidney stones Water Hyponatremia
American Urological Association
American College of Physicians
Randomized clinical trial
Research work for this review was supported by Otsuka America Pharmaceutical, Inc. Editorial assistance was provided by Catherine Fontana and Geoff Marx of BioScience Communications (New York, NY), which was funded by Otsuka. The investigators also acknowledge support from the Rare Kidney Stone Consortium (U54KD083908), a member of the NIH Rare Diseases Clinical Research Network (RDCRN), funded by the NIDDK and the National Center for Advancing Translational Sciences (NCATS), and the Mayo Clinic O’Brien Urology Research Center (U54 DK100227).
Conflict of interest
Wisit Cheungpasitporn, Stephen B. Erickson have nothing to disclose. Sandro Rossetti and Keith Friend are employees of Otsuka America Pharmaceutical, Inc. John C. Lieske Supported by the Mayo Clinic O’Brien Urology Research Center and Rare Kidney Stone Consortium, member of the National Institutes of Health Rare Diseases Clinical Research Network, and funded by the National Institute of Diabetes and Digestive, Kidney Diseases and National Center for Advancing Translational Sciences, and Otsuka America Pharmaceutical, Inc.
- 9.Bao Y, Wei Q (2012) Water for preventing urinary stones. Cochrane Database Syst Rev 6:CD004292Google Scholar